U.S. Overweight, Obesity Rates Set to Continue Increasing to 2050
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 21, 2024 -- Based on the current trajectory, overweight and obesity will continue increasing in the United States up to 2050, according to a study published online Nov. 14 in The Lancet.
Marie Ng, Ph.D., from the Institute for Health Metrics and Evaluation in Seattle, and colleagues extracted self-reported and measured anthropometric data from 134 unique sources to estimate the prevalence of overweight and obesity from 1990 to 2021 and forecast prevalence to 2050 for children and adolescents and adults.
The researchers found that in the United States, an estimated 15.1 million children and young adolescents (5 to 14 years), 21.4 million older adolescents (aged 15 to 24 years), and 172 million adults (aged 25 years and older) had overweight or obesity in 2021. Over time, the prevalence of obesity has outpaced the increase in overweight, especially among adolescents. The percentage change in the age-standardized prevalence of obesity increased by 158.4 and 185.9 percent among male and female adolescents, respectively, between 1990 and 2021; for adults, the percentage change was 123.6 and 99.9 percent for men and women, respectively. An additional 3.33 million children and young adolescents, 3.41 million older adolescents, and 41.4 million adults will have obesity by 2050 if past trends and patterns continue. The total number of children and adolescents with overweight and obesity will reach 43.1 million by 2050, and the total number of adults will reach 213 million.
"Existing policies have not shown adequate effectiveness," the authors write. "Future strategies must involve a multifaceted, whole-system approach, taking into consideration the complex drivers of obesity."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-22 12:00
Read more
- Long-Term Exposure to Air Pollution Tied to More Hospital Admissions
- High-Flow Nasal Oxygen Noninferior to Noninvasive Ventilation for Acute Respiratory Failure
- FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara
- Cold Weather Deaths Keep Rising for Americans
- Inflammatory Bowel Disease on the Rise Globally in the Elderly
- Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions